1. Introduction {#sec1}
===============

Kaposi\'s sarcoma (KS) became an AIDS-defining illness at the outset of the human-immunodeficiency-virus-(HIV-) induced acquired immunodeficiency syndrome (AIDS) endemic and pandemic \[[@B1]--[@B3]\]. There has been a striking increase in incidence of KS in both men and women compatible with the evolution of the AIDS epidemic in sub-Saharan Africa \[[@B4], [@B5]\]. In HIV/AIDS endemic regions such as sub-Saharan Africa, purplish/violaceous skin lesions should arise a high degree of awareness and suspicion of KS. However, the clinical picture of KS may mimic a variety of non-KS lesions. Furthermore, the histopathological expression of KS encompasses a large number of mimics too \[[@B6]\]. Finally, not all KS are HIV-related \[[@B3]\].

Sub-Saharan Africa in general and South Africa in particular are at the epicenter of the HIV/AIDS endemic. Although the prevalence rates vary somehow according to the sources, it was estimated that in 2010 it infected 17.8 percent of the South African population and up to 19.7 percent of females aged between 15 and 45 years \[[@B7]\]. Because of the opt-in policy for testing (voluntary counseling and testing) and the arguable widespread risk of discrimination after disclosure of positivity necessary for access to antiretroviral treatment (ART), an undefined portion of the population\'s HIV status remains undiagnosed, unknown, or undisclosed \[[@B8]\].

The human herpes virus-8 (HHV-8) or Kaposi\'s sarcoma associated herpes virus (KSHV) was identified as the infectious agent of all types of KS (classic/sporadic, iatrogenic/posttransplant, endemic/African, and AIDS-related/HIV-associated) \[[@B9]\]. The latent nuclear antigen-1 (LAN-1) of HHV-8 is expressed in all cells infected by the virus \[[@B10]\]. The immunohistochemical identification of HHV-8 by LAN-1 has become the "gold standard" in the diagnosis of KS and the differential diagnosis with its mimics. It has been shown to have a high specificity and sensitivity for the diagnosis of KS \[[@B11]--[@B14]\].

Because of prognostic and therapeutic implications of a correct diagnosis, it is recommended to biopsy any skin lesion susceptible of being KS, especially in HIV/AIDS endemic regions. We report an observational cohort of 490 consecutive skin biopsies in HIV-infected and noninfected patients. All biopsies were immunostained with HHV-8 LANA-1; 261 (53.3%) were biopsy-proven cases of KS among a group comprising 248 (50.6%) HIV-infected patients. We investigated the rates of clinical and histological diagnostic proficiency of KS and of its clinical and histopathological mimics.

2. Methods {#sec2}
==========

2.1. Site and Population {#sec2.1}
------------------------

The study was carried out in the Limpopo Province of South Africa. All surgical pathology specimens of public health facilities are centralized at the National Health Laboratory Service in the provincial capital, Polokwane. It serves an essentially rural population in excess of 5 Million. The study was approved by the research ethics committee. All the cases were treated anonymously.

2.2. Data Collection {#sec2.2}
--------------------

The cases were collected from April 2010 through December 2011. All the patients were of African ethnicity. The following information was recorded: age, gender, HIV status (when available), ART status, CD4+ T lymphocyte count, site of biopsy, and clinical provisional diagnosis. Only 25 biopsies were referred by specialist dermatologists.

All of the cases were routinely streptavidin-biotin-peroxidase immunostained with diaminobenzidine using a murine monoclonal antibody directed against the C-terminus of the LAN-1 molecule of HHV-8 (clone 13b10; Novocastra, New Castle upon Tyne, UK). The initial histopathological diagnosis was made before LAN-1 immunostaining and corrected accordingly when indicated in retrospect. The clinical and histopathological diagnostic proficiency was expressed in terms of concordance or discordance. Discordance was further subdivided into overdiagnosis (non-KS) and underdiagnosis (KS missed).

Statistical analysis was performed using column statistics, Student\'s *t* test, and 95% confidence intervals (CI) of proportions. The level of significance was set at *P* \< 0.05.

3. Results {#sec3}
==========

Out of 490 cases, 261 (53.3%) were HHV-8 proven cases of KS. The rate of documented HIV positivity among the 490 cases was 248 (50.6%). Eighty-one (32.7%) were documented to be on ART and 24 (9.7%) not to be on ART. The average CD4++ count was 259.0 ± 181.6 cells/mm^3^ (median: 214.0; range: 6.0--674).

Among the 261 cases of KS, 161 (61.7%) were known to be HIV-infected; no HIV serostatus was known for the 100 others. Among the KS with unknown HIV status, 52 were males and 48 females. One KS only was HIV negative at the time of biopsy.

[Table 1](#tab1){ref-type="table"} shows the average ages by gender, HIV status, and diagnosis of KS. There was no statistically significant difference between the groups.

The anatomical site of KS, illustrated in [Table 2](#tab2){ref-type="table"}, was known in 212 (81.2%) cases. The lower limbs were affected in 43.4%; the lesions were disseminated in 29.7%. The head was significantly involved in the HIV unknown serostatus, while dissemination was significantly more common in the documented HIV-infected patients.

[Table 3](#tab3){ref-type="table"} lists the distribution by histopathological stage. There was no significant difference in distribution of stages between the patients with unknown HIV serostatus and documented HIV-positive cases.

[Table 4](#tab4){ref-type="table"} illustrates the biopsy-proven non-KS skin lesions according to the HIV status. Pyogenic granuloma and seborrheic keratosis represented close to half of the non-KS lesions.

The histological rate of discordance, shown in [Table 5](#tab5){ref-type="table"}, was 9.2%; 18 KS were missed, and 23 non-KS were overdiagnosed. Fibrous histiocytoma (*n* = 9), pyogenic granuloma (*n* = 5), and seborrheic keratosis (*n* = 8) were misdiagnosed as nodular stage and early patch KS, respectively.

[Figure 1](#fig1){ref-type="fig"} shows the flow chart indicating that no clinical provisional diagnosis was provided in 49 (18.8%) biopsy-proven KS, and in 120 (52.4%) of non-KS skin lesions. The total clinical discordance rate was 30.5%; in 48 (15.0%) with provisional clinical diagnosis, KS was overdiagnosed, and, in 59 (18.4%), the diagnosis of KS was missed clinically. Seborrheic keratosis and pyogenic granuloma accounted for half of the total clinical discordance rate.

4. Discussion {#sec4}
=============

Kaposi\'s sarcoma is a multifaceted entity in terms of the population groups (ethnic and gender) it affects, in terms of clinical signs and symptoms, in terms of the body parts it affects (skin, mucosa, lymph nodes, viscera), and in terms of histopathological expression. Traditionally, the six histological variants are the early patch stage, the nodular stage, the plaque stage, the intravascular, the lymphangioma-like, and the angiosarcoma-like type \[[@B15]\]. Recently, more than ten additional variants have been described \[[@B16], [@B17]\].

In sub-Saharan Africa, KS accounts for about 10.0% of HIV-related malignancies and may be the first manifestation of HIV \[[@B18]\]. As such, the diagnosis of KS may in many instances serve as an entry into the treatment circuit, provided consent is given for HIV testing. Patients with AIDS-associated KS present mostly with advanced disease resulting in high mortality \[[@B19]\]. Although KS regresses under ART, the relatively wide unavailability of ART, and the threshold of a CD4+ count of ≤200 in South Africa as entry criterion into the ART circuit result in a rapid progression of the disease \[[@B20], [@B21]\]. This illustrates not only the importance of an early and correct diagnosis of the disease but also of the willingness to undergo HIV testing.

Clinically, virtually all pigmented skin lesions are part of the differential diagnosis of KS \[[@B22]\]. In black subjects, the clinical recognition of KS is likely to be even more difficult than in nonblack subjects. This underscores the need of a biopsy-proven diagnosis. Because of the vast spectrum of vasoproliferative mimics of KS illustrated in [Table 6](#tab6){ref-type="table"}, HHV-8 LAN-1 immunohistochemistry has become the gold standard of diagnosis \[[@B16], [@B22]--[@B24]\].

The increasing prevalence of HIV infection in sub-Saharan Africa together with the reluctance to be tested makes it difficult to distinguish the endemic KS from the AIDS-associated variant \[[@B5]\]. The distinction has prognostic implications since endemic KS evolves much slower and less aggressively than the AIDS-associated variant. In a Tanzanian study of 105 clinically suspected KS, 77 (73.3%) were confirmed on biopsy (without HHV-8 LAN-1 confirmation though); 11 (14.3%) occurred in HIV-negative subjects. The majority (63.6%) of the endemic KS cases was in the ≥50 years of age group; the lesions were limited exclusively to the lower limbs, and all were males \[[@B5]\]. In our series of KS with unknown HIV serostatus, there were an almost equal number of males and females, with a similar mean age and distribution by histological stage as the documented HIV-positive KS. In terms of anatomical distribution, half were limited exclusively to the lower limbs. These data suggest that at least half of the patients with unknown HIV status were likely to be actually HIV infected. A Kenyan study has shown that, currently, endemic and HIV-related exhibit similar clinical presentation and natural history \[[@B25]\]. In an Ugandan study of 197 adults with HIV and KS, on the contrary, 55 percent were women; they were less likely to have lower limb lesions and more likely to have facial lesions than men. The authors suggested that gender affects the pathophysiology of KS \[[@B26]\].

5. Conclusion {#sec5}
=============

The present study shows a relatively high discordance rate between the clinical and the biopsy-proven diagnosis of KS, indicating that "violaceous" skin lesions in an HIV endemic population warrant a biopsy. The relatively high histological discordance between the pre- and post-immunohistochemical diagnosis of KS warrants HHV-8 immunophenotyping to ascertain the diagnosis.
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###### 

Age distribution by gender, HIV serostatus, and Kaposi\'s sarcoma.

                       Male                     Female                 *t*    *P*
  -------------------- ------------------------ ---------------------- ------ ------
  HIV seropositive     41.6 ± 12.6 \[41.0\]\*   40.5 ± 10.7 \[38.0\]   0.46   0.15
  HIV status unknown   41.7 ± 18.0 \[43.0\]     41.1 ± 18.8 \[39.0\]   0.21   0.84
  Biopsy-proven KS     41.1 ± 14.1 \[40.0\]     42.2 ± 15.7 \[39.5\]   0.54   0.59

\* Values are mean ± SD \[median\].

###### 

Distribution by anatomical sites of Kaposi\'s sarcoma: HIV-positive *versus* unknown serostatus.

  Site           Males HIV positive *n* (%)   Females HIV positive *n* (%)   Total HIV positive *n* (%)   Males HIV status unknown *n* (%)   Females HIV status unknown *n* (%)   Total HIV status unknown *n* (%)
  -------------- ---------------------------- ------------------------------ ---------------------------- ---------------------------------- ------------------------------------ ----------------------------------
  Head           7 (8.8)\*                    4 (7.0)\*                      11 (8.0)^†^                  9 (23.7)\*                         9 (24.3)\*                           18 (24.0)^†^
  Trunk          5 (6.3)                      1 (1.8)                        6 (4.4)                      3 (7.9)                                                                 3 (4.0)
  Upper limbs    4 (5.0)                      1 (1.8)                        5 (3.6)                      3 (7.9)                            3 (8.1)                              6 (8.0)
  Lower limbs    34 (42.5)                    23 (40.3)                      57 (41.6)                    17 (44.7)                          18 (48.6)                            35 (46.7)
  Perineal       1 (1.3)                      4 (7.0)                        5 (3.6)                      1 (2.6)                            2 (5.4)                              3 (4.0)
  Disseminated   29 (36.2)                    24 (42.1)                      53 (38.7)^†^                 5 (13.2)                           5 (13.5)                             10 (13.3)^†^
  Unknown        4 (4.8)\*\*                  20 (26.0)\*\*                  24 (14.9)\*\*                14 (36.8)\*\*                      11 (22.9)\*\*                        25 (25.0)\*\*
                                                                                                                                                                                  
  Total          84                           77                             161                          52                                 48                                   100

\*% of the total number of known anatomical sites; \*\* % of the total number of cases; ^†^ statistically significant 95% confidence intervals (CIs).

###### 

Distribution by stage of Kaposi\'s sarcoma: HIV-positive *versus* unknown serostatus.

  Stage         Males HIV positive *n* (%)   Females HIV positive *n* (%)   Total HIV positive *n* (%)   Males HIV status unknown *n* (%)   Females HIV status unknown *n* (%)   Total HIV status unknown *n* (%)
  ------------- ---------------------------- ------------------------------ ---------------------------- ---------------------------------- ------------------------------------ ----------------------------------
  Early patch   45 (53.6)                    35 (45.5)                      80 (49.7)                    21 (40.3)                          15 (31.3)                            36 (36.0)
  Plaque        9 (10.7)                     17 (22.1)                      26 (6.1)                     7 (13.5)                           7 (14.5)                             14 (14.0)
  Nodular       30 (35.7)                    25 (32.4)                      55 (34.2)                    24 (46.2)                          26 (54.2)                            50 (50.0)
                                                                                                                                                                                 
  Total         84                           77                             161                          52                                 48                                   100

###### 

Biopsy-proven non-Kaposi\'s sarcoma skin lesions and HIV status.

  Pathology                  HIV seropositive *n* (%)   HIV serostatus unknown *n* (%)   Total *n* (%)
  -------------------------- -------------------------- -------------------------------- ---------------
  Pyogenic granuloma         24 (27.6)                  39 (27.5)                        63 (27.5)
  Seborrheic keratosis       29 (33.3)                  22 (15.5)                        51 (22.3)
  Haemangioma                4 (4.6)                    33 (23.2)                        37 (16.2)
  Fibrous histiocytoma       4 (4.6)                    21 (14.8)                        25 (10.9)
  Drug reaction vasculitis   5 (5.7)                    1 (0.7)                          6 (2.6)
  Melanocytic melanoma       3 (3.4)                    2 (1.4)                          5 (2.2)
  Varia                      18 (20.8)                  24 (16.9)                        42 (18.3)
                                                                                         
  Total                      87                         142                              229

###### 

Histological diagnostic discordance before immunohistochemistry.

  Pathology                  Overdiagnosis of KS *n* (%)   Underdiagnosis of KS *n* (%)   Total discordance rate *n* (%)
  -------------------------- ----------------------------- ------------------------------ --------------------------------
  Seborrheic keratosis       8 (29.6)                      7 (38.9)                       15 (33.3)
  Fibrous histiocytoma       9 (33.3)                      3 (16.7)                       12 (26.7)
  Pyogenic granuloma         5 (18.5)                      5 (27.8)                       10 (22.2)
  Drug reaction vasculitis   3 (11.1)                      3 (16.7)                       6 (13.3)
  Haemangioma                2 (7.4)                                                      2 (4.4)
                                                                                          
  Total                      27                            18                             41/490 (9.2)

###### 

Differential diagnosis of Kaposi\'s sarcoma.

  Patch stage                                                           Plaque stage                             Nodular stage                        Aggressive late stage
  ---------------------------------- ---------------------------------- ---------------------------------------- ------------------------------------ ---------------------------------
  Early macular                      Late macular                                                                                                     
                                                                                                                                                      
  Pyogenic granuloma                 Well-differentiated angiosarcoma   Angioendotheliomatosis                   Pyogenic granuloma                   Desmoplastic malignant melanoma
  Acroangiodermatitis                Bacillary angiomatosis             Fibrosarcoma                                                                  
                                                                                                                                                      
  Atrophic histiocytoma              Progressive lymphangioma           Benign-disseminated angioproliferation   Spindle cell hemangioma              Leiomyosarcoma
  Kaposi-form hemangioendothelioma   Monophasic synoviosarcoma                                                                                        
                                                                                                                                                      
  Benign lymphangioendothelioma      Microvenular hemangioma            Dermatomyofibroma                        Cutaneous leiomyosarcoma             
                                     Granuloma annulare                 Targetoid hemosideric angioma            Cutaneous angiosarcoma               
                                                                                                                 Hypertrophic scar                    
                                                                                                                 Dermatofibroma/sarcoma protuberans   
                                                                                                                 Neurofibroma                         
                                                                                                                 Spindle cell melanoma                
                                                                                                                 Fibrous histiocytoma                 
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